The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment.


Journal

Neurobiology of aging
ISSN: 1558-1497
Titre abrégé: Neurobiol Aging
Pays: United States
ID NLM: 8100437

Informations de publication

Date de publication:
07 2021
Historique:
received: 20 06 2020
revised: 10 01 2021
accepted: 26 01 2021
pubmed: 28 2 2021
medline: 24 12 2021
entrez: 27 2 2021
Statut: ppublish

Résumé

We report a case of childhood-onset ALS with a FUS gene mutation presenting cognitive impairment and a rapid clinical progression. The patient, an 11-year-old girl, presented with right distal upper limb weakness and mild intellectual disability at the Griffith Mental Development Scales. The disease rapidly worsened and the patient became tetraplegic and bed-ridden 2 years after symptom onset. A c.1509_1510delAG mutation in exon 14 of the FUS gene was detected, resulting in a predicted truncated protein, p.G504Wfs*12, lacking the nuclear localization signal. The levels of FUS mRNA in the proband were not significantly different compared to controls. Western immunoblot analysis showed that one antibody (500-526) detected in the proband ~50% of the amount of FUS protein compared to controls, while 3 other antibodies (2-27, 400-450 and FUS C-terminal), which recognize both wild type and the mutated FUS, detected 60% to 75% of the amount of the protein. These findings indicate that p.G504Wfs*12 FUS is more prone to undergo post-translational modification respect to wild type FUS.

Identifiants

pubmed: 33637330
pii: S0197-4580(21)00036-1
doi: 10.1016/j.neurobiolaging.2021.01.029
pii:
doi:

Substances chimiques

RNA, Messenger 0
RNA-Binding Protein FUS 0

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

130.e1-130.e7

Informations de copyright

Copyright © 2021. Published by Elsevier Inc.

Auteurs

Paola Lanteri (P)

Neurophysiopathology Centre, Department of Diagnostics and Applied Technology, Fondazione IRCCS, Istituto Neurologico "C. Besta", Milan, Italy.

Irene Meola (I)

Child Neurology Unit, Cesare Arrigo Children's Hospital, Alessandria, Italy.

Antonio Canosa (A)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.

Giovanni De Marco (G)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.

Annarosa Lomartire (A)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.

Maria Teresa Rinaudo (MT)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.

Emilio Albamonte (E)

The NEMO Clinical Center (NEuroMuscular Onmicenter), Milan, Italy.

Valeria Ada Sansone (VA)

The NEMO Clinical Center (NEuroMuscular Onmicenter), Milan, Italy; Neurorehabilitation Unit, University of Milan, Milan, Italy.

Christian Lunetta (C)

The NEMO Clinical Center (NEuroMuscular Onmicenter), Milan, Italy.

Umberto Manera (U)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.

Rosario Vasta (R)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.

Cristina Moglia (C)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.

Andrea Calvo (A)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy.

Paola Origone (P)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOGMI) University of Genoa and IRCCS Policlinico San Martino, Genoa, Italy; IRCCS Policlinico San Martino, Genoa, Italy.

Adriano Chiò (A)

'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy; Neurology 1, ALS Center, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin, Italy; Institute of Cognitive Sciences and Technologies, C.N.R, Rome, Italy. Electronic address: adriano.chio@unito.it.

Paola Mandich (P)

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal and Child Health (DINOGMI) University of Genoa and IRCCS Policlinico San Martino, Genoa, Italy; IRCCS Policlinico San Martino, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH